Teradyne: president Mills sells $73k in stock

Regan Mills sold 252 TER shares on Apr 2, 2026 for $73,301 at $290.88 and had 222 shares withheld on Apr 1 (taxes) valued at $69,308 at $312.20; Mills now directly owns 11,415.3452 shares. Teradyne shares trade at $309.61, up 314% over the past year and 113% over six months, while InvestingPro flags the stock as overvalued with a P/E of 88.68. The company launched Photon 100 (silicon photonics / co‑packaged optics test platform) and Omnyx (PCB assembly test platform for AI/datacenter), and analysts raised targets — Morgan Stanley to $306 (Equalweight) and Cantor Fitzgerald to $330 — with Aletheia issuing a positive outlook.

Analysis

A hardware test company pivoting into higher-growth AI and photonics adjacencies creates asymmetric outcomes across the ecosystem: backend OSATs and contract test houses pick up near-term incremental demand while hyperscaler-facing server/system vendors get a multi-quarter tailwind if the test cycle sustains. Because a handful of large customers can drive a material step-change in quarterly bookings, revenue volatility will be binary — a few announced design wins or factory ramps can re-rate multiples quickly, and conversely an order delay will show up as sharp sequential weakness.

The primary execution risk is calendarization: new platform revenue for novel technologies typically takes 12–36 months to move from pilot to high-margin volume, and that timing gap will determine whether the market awards durable multiple expansion or simply a one-time sentiment pump. Geographic and customer concentration (hyperscalers + Taiwan manufacturing base) amplifies policy/export-control and cyclical inventory risks; any signs of capex pause at the largest customers would be an immediate negative catalyst.

The consensus appears to be pricing rapid share capture; that’s the contrarian lever. If the company converts wins into recurring service/consumable revenue and maintains gross-margin leverage, upside is asymmetric; if wins are small pilots or the competitive response from legacy ATE vendors blunts pricing, downside from multiple compression is equally real. Monitor sequential bookings composition (pilot vs. production), multi-quarter backlog conversion, and gross-margin on new-platform shipments as the three single best datapoints to adjudicate whether to add or trim exposure.

Key Decisions for Investors

• Directional long (defined risk): Buy a 12–24 month call spread on TER (e.g., long Jan-2028 calls / short higher strike Jan-2028 calls) sized as 2–4% notional. Rationale: limited premium at risk with 2–4x upside if production ramps materialize within 12–24 months; max loss = premium paid, target payoff if new-platform wins translate to durable revenue growth.
• Relative-value pair (execution vs incumbents): Go long TER / short ATEYY (Advantest) on a 12-month horizon, weighting long ~60% / short ~40% notional to reflect execution risk. Rationale: expresses view that execution on AI/photonic test stacks will outpace a larger incumbent; target relative outperformance 15–25% over 12 months, stop the pair if TER underperforms by 10% on a 30-day basis.
• Downside protection for existing equity holders: Buy 3-month ATM puts sized to cover 30–50% of your long position or purchase a short-dated put calendar to hedge event risk around the next earnings/bookings release. Rationale: caps short-term headline risk (order timing or guidance misses) at a predictable cost while preserving long-term upside optionality.
• Event-driven short (tactical): Initiate a small short if upcoming quarter shows sequential dislocation in production bookings (pilot-heavy backlog without firm PO cadence) — target a 20–30% return if market punishes execution, with a strict stop-loss of 10% against the entry. Rationale: market rewards concrete production wins; a gap between bookings language and real POs is a high-probability catalyst for mean reversion in sentiment.